PMID- 37288295
OWN - NLM
STAT- MEDLINE
DCOM- 20230612
LR  - 20230612
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic 
      review and meta-analysis.
PG  - 1158153
LID - 10.3389/fendo.2023.1158153 [doi]
LID - 1158153
AB  - OBJECTIVE: To assess the relationship between use of sodium-glucose 
      cotransporter-2 inhibitors (SGLT2i) and the risk of gout among patients with type 
      2 diabetes mellitus (T2DM). METHODS: A systemic review and meta-analysis were 
      designed by reviewing articles published between 2000 January 1 and 2022 December 
      31 using PubMed system and Web of Science system based on the PRISMA 2020 
      guidelines. The end point of interest was gout (including gout flares, gout 
      events, starting uric-acid lowering therapy and starting anti-gout drugs use) 
      among patients with T2DM using SGLT2i versus not using SGLT2i. A random-effects 
      model was utilized to measure the pooled hazard ratio (HR) with 95% confidence 
      interval (CI) for the risk of gout associated with SGLT2i use. RESULTS: Two 
      prospective post-hoc analyses of randomized controlled trials and 5 retrospective 
      electronic medical record-linkage cohort studies met the inclusion criteria. The 
      meta-analysis demonstrated that there was a decreased risk of developing gout for 
      SGLT2i use as comparing with non-use of SGLT2i among patients with T2DM (pooled 
      HR=0.66 and 95%CI=0.57-0.76). CONCLUSIONS: This meta-analysis demonstrates that 
      SGLT2i use is associated with a 34% decreased risk of developing gout among 
      patients with T2DM. SGLT2i may be the treatment options for patients with T2DM 
      who are at high risk of gout. More randomized controlled trials and real-world 
      data are needed to confirm whether there is a class effect of SGLT2i for the risk 
      reduction of gout among patients with T2DM.
CI  - Copyright (c) 2023 Lai, Hwang, Kuo, Liu and Liao.
FAU - Lai, Shih-Wei
AU  - Lai SW
AD  - Department of Public Health, College of Public Health, China Medical University, 
      Taichung, Taiwan.
AD  - Department of Medicine, College of Medicine, China Medical University, Taichung, 
      Taiwan.
AD  - Department of Family Medicine, China Medical University Hospital, Taichung, 
      Taiwan.
FAU - Hwang, Bing-Fang
AU  - Hwang BF
AD  - Department of Occupational Safety and Health, College of Public Health, China 
      Medical University, Taichung, Taiwan.
FAU - Kuo, Yu-Hung
AU  - Kuo YH
AD  - Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan.
FAU - Liu, Chiu-Shong
AU  - Liu CS
AD  - Department of Medicine, College of Medicine, China Medical University, Taichung, 
      Taiwan.
AD  - Department of Family Medicine, China Medical University Hospital, Taichung, 
      Taiwan.
FAU - Liao, Kuan-Fu
AU  - Liao KF
AD  - College of Medicine, Tzu Chi University, Hualien, Taiwan.
AD  - Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu 
      Chi Hospital, Taichung, Taiwan.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230523
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Placebos)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - *Gout/chemically induced/etiology
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Humans
MH  - Male
MH  - Female
MH  - Middle Aged
MH  - Placebos
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor/antagonists & inhibitors
PMC - PMC10242385
OTO - NOTNLM
OT  - diabetes mellitus
OT  - gout
OT  - meta-analysis
OT  - randomized controlled trials (RCT)
OT  - sodium-glucose cotransporter-2 inhibitor (SGLT2i)
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/08 06:42
MHDA- 2023/06/09 06:42
PMCR- 2023/01/01
CRDT- 2023/06/08 04:32
PHST- 2023/02/11 00:00 [received]
PHST- 2023/05/04 00:00 [accepted]
PHST- 2023/06/09 06:42 [medline]
PHST- 2023/06/08 06:42 [pubmed]
PHST- 2023/06/08 04:32 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1158153 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 May 23;14:1158153. doi: 
      10.3389/fendo.2023.1158153. eCollection 2023.